• Product NameVorinostat (SAHA, MK0683)
• Brief DescriptionInhibitors
• Purification99.47%
• Biological ActivityVorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin Y, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
• Target NameHDAC inhibitor
• CAS No. 149647-78-9
• Calculated MW 264.32
• Formulation C14H20N2O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
  Pathways:Chromatin/Epigenetic; DNA Damage/DNA Repair; NF-κb
  Receptor:HDAC; HDAC1;HDAC2;HDAC3;HDAC6;HDAC8
  Boling pt:
  Melting pt:161-162C
  Solubility:Ethanol: 3 mg/mL (11.35 mM); DMSO: 53 mg/mL (200.52 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Xu WS, et al. Oncogene. 2007 Aug 13; 26(37): 5541-52.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting